SCHEDULE: Janus Henderson Discloses 7.4% Stake in Immix Biopharma

Janus Henderson Group plc has reported a 7.4% beneficial ownership stake in Immix Biopharma, Inc. common stock as of December 31, 2025.

Summary

• Janus Henderson Group plc, a Jersey-based parent holding company, beneficially owns 3,921,568 shares of Immix Biopharma, Inc. common stock.
• This ownership represents 7.4% of Immix Biopharma's common stock class.
• The shares are held through various Asset Managers under Janus Henderson, who exercise shared voting and dispositive power over these securities on behalf of their Managed Portfolios.
• The Managed Portfolios, including the Janus Henderson Biotech Innovation Master Fund Ltd., retain the right to receive dividends and proceeds from the sale of these securities.
• The acquisition and holding of these securities are certified to be in the ordinary course of business and not for the purpose of changing or influencing control of Immix Biopharma.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake by Janus Henderson Group plc suggests a vote of confidence in Immix Biopharma's prospects, although it is a routine disclosure without specific performance details.

Positives

• A significant institutional investor, Janus Henderson Group plc, has taken a 7.4% stake in Immix Biopharma, indicating potential confidence in the company's long-term prospects.
• The investment is held through various Asset Managers, suggesting a diversified approach to the holding.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant stake by a major asset manager like Janus Henderson in a biopharma company like Immix Biopharma can signal institutional validation and potentially attract further investor interest, especially in a sector known for high risk and high reward. Such investments often reflect a long-term view on the company's pipeline or market position.

Comparison to Industry Standards

• StockSavvy.ai observes that institutional ownership levels vary widely across the biopharma sector. While a 7.4% stake by a single institutional group is notable, it is not uncommon for emerging biopharma companies to have significant portions of their stock held by a few large institutional investors or specialized biotech funds, such as the Janus Henderson Biotech Innovation Master Fund Ltd. mentioned in the filing. This level of ownership is generally considered a strong vote of confidence, aligning with similar institutional positions seen in companies like smaller-cap biotech firms where specialized funds often take substantial early positions.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 7.4% stake may increase confidence and potentially attract other investors, positively impacting share price stability and liquidity.
• Management: The presence of a large institutional holder can lead to increased scrutiny and engagement from the investor, potentially influencing strategic decisions, though the filing states the investment is not for control purposes.

Key Dates

Recommendation

The disclosure of a significant institutional stake by Janus Henderson Group plc is a positive signal, indicating professional investor interest and potential long-term confidence in Immix Biopharma. However, this filing is a routine ownership disclosure and does not provide new operational or financial performance data to warrant a 'buy' recommendation. It primarily confirms an existing or recently established position by a major asset manager. Investors should 'hold' and await further operational updates or financial results from Immix Biopharma to make a more informed decision.

Keywords

Immix Biopharma, Janus Henderson, Beneficial Ownership, Institutional Investment, Common Stock, Biopharma, SEC Filing, Schedule 13G, Investment Management